In vitro and in vivo analyses of eFAP: a novel FAP-targeting small molecule for radionuclide theranostics and other oncological interventions.
Circe D van der HeideHanyue MaMark W H HoorensJoana D CampeiroDebra C StuurmanCorrina M A de RidderYann SeimbilleSimone U DalmPublished in: EJNMMI radiopharmacy and chemistry (2024)
The superior affinity and faster tumor accumulation of eFAP-6 over FAPI-46 makes it a suitable compound for radionuclide imaging. After further optimization, the eFAP series has great potential for various oncological interventions, including fluorescent-guided surgery and effective targeted radionuclide theranostics.
Keyphrases
- small molecule
- rectal cancer
- cancer therapy
- physical activity
- radical prostatectomy
- minimally invasive
- robot assisted
- high resolution
- coronary artery bypass
- quantum dots
- prostate cancer
- protein protein
- living cells
- drug delivery
- human health
- risk assessment
- coronary artery disease
- surgical site infection
- climate change
- percutaneous coronary intervention
- label free
- photodynamic therapy